Amitriptyline Washout Period
Amitriptyline requires approximately 3.5 to 4 days (85-96 hours) to wash out after the last dose, based on its elimination half-life of approximately 17 hours and the standard pharmacokinetic principle that 5 half-lives are needed for >97% drug elimination.
Pharmacokinetic Basis for Washout
The washout period is calculated using amitriptyline's elimination half-life:
- Amitriptyline has a biological half-life of approximately 17 hours when administered intravenously, which represents the most accurate pharmacokinetic measurement 1
- Complete drug elimination requires at least 5 half-lives, as established by consensus guidelines for therapeutic drug monitoring 2
- This translates to 85 hours (approximately 3.5 days) for amitriptyline to be essentially eliminated from the system 1
Metabolism and Active Metabolites
The washout calculation becomes more complex when considering active metabolites:
- Amitriptyline is rapidly metabolized to nortriptyline, its active metabolite, primarily through N-demethylation 3, 4
- Nortriptyline formation occurs rapidly, with 30-67% produced during first-pass metabolism through the liver 4
- The total amount of nortriptyline entering systemic circulation is approximately one-quarter of the amitriptyline dose 4
- Virtually the entire dose is excreted as glucuronide or sulfate conjugates of metabolites within 24 hours, with little unchanged drug appearing in urine 3
Clinical Washout Period Recommendation
For practical clinical purposes, allow 1 week (7 days) for complete washout to account for:
- Individual pharmacokinetic variability 2
- The presence of active metabolite nortriptyline 4
- Genetic polymorphisms in CYP2D6 metabolism that can significantly affect elimination rates 2
- Potential drug interactions that may prolong elimination 5
Important Clinical Considerations
Factors That Prolong Washout
- Hepatic insufficiency significantly affects elimination since amitriptyline undergoes extensive hepatic metabolism 2
- CYP2D6 poor metabolizers (5-8% of Caucasians) may have substantially prolonged elimination 2
- Recent use of CYP2D6 inhibitors can dramatically extend washout periods—terbinafine, for example, can cause clinically significant interactions for at least 3 months after discontinuation 5
- Chronic use with high doses may require longer washout periods due to tissue accumulation 6, 7
Withdrawal Phenomena vs. Washout
- Withdrawal symptoms can occur within the first 2 weeks of discontinuation, consisting of irritability, dream and sleep disturbance, and restlessness 6, 7
- These withdrawal symptoms are distinct from pharmacokinetic washout and represent neuroadaptive changes rather than drug presence 7
- Withdrawal reactions should not be confused with incomplete drug elimination when timing subsequent interventions 7
Practical Algorithm for Clinical Decision-Making
Standard patients (normal hepatic function, no CYP2D6 inhibitors):
Patients with hepatic impairment:
- Wait 10-14 days minimum 2
Patients recently on CYP2D6 inhibitors (e.g., terbinafine, fluoxetine, paroxetine):
- Wait at least 3 months if terbinafine was used 5
- Consider therapeutic drug monitoring if timing is critical 2
Patients with unknown CYP2D6 status and concerning symptoms: